



Ongoing Trials – status update

ICON 9



An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Trial Schema



Stratified by 6-12 vs >12 month progression free interval; surgery vs no surgery at relapse prior to chemotherapy; prior bevacizumab therapy; BRCA status; HRD status

Olaparib: 300 mg BD
Cediranib: 20 mg OD

Sponsor: University College London

Recruitment target: 618

Study Objectives

To assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance of olaparib alone in patients who have received combination platinum-based chemotherapy

Primary Endpoints

PFS (RECIST v1.1) and OS

Updates

- 35 UK sites, 45 international sites from 5 countries
- September 2015: Full CRUK application approved in UK
- Funding approved in Australia and Canada
- Contract signed with AZ in December 2016
- Trial design update submitted to funders
- Target open date: Q4 2017

